Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome

Wollny, Tomasz; Daniluk, Tamara; Piktel, Ewelina; Wnorowska, Urszula; Bukłaha, Anna; Głuszek, Katarzyna; Durnaś, Bonita; Bucki, Robert

doi:10.3390/pathogens10121545

Cited by 6 publications

(4 citation statements)

References 115 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect might through improved gut microbiota disorders such as increase relative abundance of Bifidobacterium and Muribaculum genera and decrease relative abundance of Sutterella genus to elevate levels of SCFAs or reduce levels of pro-inflammatory cytokines. In the clinical treatment of IBS, probiotics are widely used in managements of gut microbiota disorders [ 99 ]. However, because of varieties of strains and combinations, which particular combination, species or strains of probiotics are effective for IBS remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines

et al. 2022

View full text Add to dashboard Cite

Purpose Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probiotic cocktail widely used in gastrointestinal disorders which relate to the imbalance of gut microbiota. However, the efficacy and potential mechanisms of Bifico treatment in IBS remains incompletely understood. Methods Adopting a wrap restraint stress (WRS) -induced IBS mice model. Protective effect of Bifico in IBS mice was examined through abdominal withdrawal reflex (AWR) scores. 16S rDNA, 1H nuclear magnetic resonance (1H-NMR) and western blot assays were performed to analyze alterations of gut microbiota, microbiome metabolites and inflammatory cytokines, respectively. Results Bifico could decrease intestinal visceral hypersensitivity. Although gut microbiota diversity did not increase, composition of gut microbiota was changed after treatment of Bifico, which were characterized by an increase of Proteobacteria phylum and Actinobacteria phylum, Muribaculum genus, Bifidobacterium genus and a decrease of Parabacteroides genus, Sutterella genus and Lactobacillus genus. Moreover, Bifico elevated the concentration of short-chain fatty acids (SCFAs) and reduced protein levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). From further Spearman’s correlation analysis, Bifidobacterium genus were positively correlated with SCFAs including propionate, butyrate, valerate and negatively correlated with IL-6 and TNF-α. Conclusion Bifico could alleviate symptoms of IBS mice through regulation of the gut microbiota, elevating production of SCFAs and reducing the colonic inflammatory response.

show abstract

Section: Discussionmentioning

confidence: 99%

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[43,44] This is relevant to IBS, where the microbiota plays an important role, and where symptoms and their severity have been shown to correlate with bacterial carbohydrate metabolism among other factors. [45-48] Future studies are warranted where the relationship between hCAZyme genotype and gut microbiota composition is investigated.…”

Section: Discussionmentioning

confidence: 99%

Functional variation in human Carbohydrate-Active enZYmes (hCAZymes) in relation to the efficacy of a FODMAP-reducing diet in IBS patients

Zamfir-Taranu,

Löscher,

Carbone

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective: Limiting the dietary intake of carbohydrates poorly absorbed in the small intestine (FODMAPs) has therapeutic effects in some but not all irritable bowel syndrome (IBS) patients. We investigated genetic variation in human Carbohydrate-Active enZYmes (hCAZymes) genes in relation to the response to a FODMAP-lowering diet in the DOMINO study. Design: hCAZy polymorphism was studied in IBS patients from the dietary (FODMAP-lowering; N=196) and medication (otilonium bromide; N=54) arms of the DOMINO trial via targeted sequencing of 6 genes of interest (AMY2B, LCT, MGAM, MGAM2, SI and TREH). hCAZyme defective (hypomorphic) variants were identified via computational annotation using clinical pathogenicity classifiers. Age- and sex-adjusted logistic regression was used to test hCAZyme polymorphisms in cumulative analyses where IBS patients were stratified into carrier and non-carrier groups (collapsing all hCAZyme hypomorphic variants into a single bin). Quantitative analysis of hCAZyme variation was also performed, in which the number of hCAZyme genes affected by a hypomorphic variant was taken into account. Results: In the dietary arm, the number of hypomorphic hCAZyme genes positively correlated with treatment response rate (P=0.03, OR=1.51 [CI=0.99-2.32]). In the IBS-D group (N=55), hCAZyme carriers were six times more likely to respond to the diet than non-carriers (P=0.002, OR=6.33 [CI=1.83-24.77]). These trends were not observed in the medication arm. Conclusions: hCAZYme genetic variation may be relevant to the efficacy of a carbohydrate-lowering diet. This warrants additional testing and replication of findings, including mechanistic investigations of this phenomenon. Keywords: Irritable bowel syndrome; nutrigenetics; lowFODMAP diet; carbohydrate maldigestion; CAZyme

show abstract

“…Although the efficacy of probiotics in relieving IBS symptoms has been widely accepted [58,59], the efficacy of FMT-delivered microbiota is controversial [60]. While several studies support its safety and effectiveness, others do not [61][62][63][64][65][66]. Thus, we conducted a subgroup meta-analysis study to elucidate some of the current controversies regarding the different features of FMT therapy in IBS patients.…”

Section: Discussionmentioning

confidence: 99%

Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Jamshidi,

Farsi,

Nariman

et al. 2023

IJMS

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) poses a significant challenge due to its poorly understood pathogenesis, substantial morbidity, and often inadequate treatment outcomes. The role of fecal microbiota transplantation (FMT) in managing IBS symptoms remains inconclusive. This systematic review and meta-analysis aimed to ascertain the effectiveness of FMT in relieving symptoms in IBS patients. A thorough search was executed on PubMed/Medline and Embase databases until 14 June 2023, including all studies on FMT use in IBS patients. We examined the efficiency of FMT in reducing patients’ symptoms overall and in particular subgroups, classified by placebo preparation, FMT preparation, frequency, and route of administration. Among 1015 identified studies, seven met the inclusion criteria for the meta-analysis. The overall symptomatology of FMT-treated IBS patients did not significantly differ from the control group (Odds Ratio (OR) = 0.99, 95% Confidence Interval (CI) 0.39–2.5). Multiple doses of FMT compared with non-FMT placebo, or single-donor FMT therapy compared with autologous FMT placebo also showed no significant benefit (OR = 0.32, 95%CI (0.07–1.32), p = 0.11, and OR = 1.67, 95%CI (0.59–4.67), p = 0.32, respectively). However, a single dose of multiple-donor FMT administered via colonoscopy (lower gastrointestinal (GI) administration) significantly improved patient symptoms compared with autologous FMT placebo (OR = 2.54, 95%CI (1.20–5.37), p = 0.01, and OR = 2.2, 95%CI (1.20–4.03), p = 0.01, respectively). The studies included in the analysis showed a low risk of bias and no publication bias. In conclusion, lower GI administration of a single dose of multiple-donor FMT significantly alleviates patient complaints compared with the autologous FMT used as a placebo. The underlying mechanisms need to be better understood, and further experimental studies are desired to fill the current gaps.

show abstract

Targeting the Gut Microbiota to Relieve the Symptoms of Irritable Bowel Syndrome

Cited by 6 publications

References 115 publications

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines

Functional variation in human Carbohydrate-Active enZYmes (hCAZymes) in relation to the efficacy of a FODMAP-reducing diet in IBS patients

Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About